A Phase 2 interventional study of Elismetrep (K-304) 2 mg and Elismetrep (K-304) 5 mg in Migraine, sponsored by TriGemX Bio, Inc.. Completed at 66 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by TriGemX Bio, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 697 studies in Migraine Disorders with a site in United States — 93 open to participants now, 115 under way, 27 of them phase 3. Migraine Disorders · United States.
Among the 697 studies in Migraine Disorders with a site in United States, this one is the 123rd largest by enrollment of the 610 interventional ones that give a count, is one of 32 that started in 2025, is one of 90 in phase 2, and was the 639th registered.
1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →93 of the 697 studies in Migraine Disorders with a site in United States are open now. Recruiting first, the newest first:
Salvia BioElectronics · Sites in United States
Ages 22–84
University of Colorado, Denver · Sites in United States
Ages 12–17
Columbia University · Sites in United States
Ages 18–55
TriGemX Bio, Inc. · Sites in United States
Ages 18–75
University of North Carolina, Chapel Hill · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
697 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 66 · Phase 2 113 · Phase 3 151 · Phase 4 101
First in 1999; this study’s year is marked. 32 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 431 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 78 across the 610 interventional studies, 195 across the 84 observational. Of the 527 that completed or were terminated, 305 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
345 of 697 have an industry lead sponsor. The 10 most frequent:
TriGemX Bio, Inc. is the lead sponsor of 5 studies on the registry; 3 are open to participants now.
TriGemX Bio, Inc. has 5 studies filed under Migraine Disorders — fewer than ten, so there is no comparison to draw.
47 of the studies in Migraine Disorders with a site in United States that are under way reach primary completion within a year, 11 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06641466Phase 3PfizerA Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine | 2026-11-29 |
| NCT07645924Phase 3TriGemX Bio, Inc.A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine | 2027-02 |
| NCT05598723Phase 3Naval Medical Center Camp LejeuneBOTOX® vs. XEOMIN® for Chronic Migraine | 2027-02-24 |
| NCT07018700Phase 3Merz Therapeutics GmbHA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine | 2027-03 |
| NCT07018713Phase 3Merz Therapeutics GmbHA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine | 2027-03 |
Add all 47 to your calendar (.ics) → With an account.
Among the 697 studies in Migraine Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep as compared to placebo in the acute treatment of migraine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Meet the following requirements:
Post hysterectomy, bilateral oophorectomy or bilateral salpingectomy, based on the participant's recall of their medical history.
OR
agrees to remain abstinent from heterosexual activity*
*Abstinence can be used as the sole method of if it is in line with the participant's preferred and usual lifestyle and if considered acceptable by local regulatory agencies and ethics committees. Periodic abstinence (e.g., calendar, ovulation, sympto-thermal, post-ovulation methods, etc.) and withdrawal are not acceptable methods of contraception.
or agrees to use (or have their partner use) a birth control method that is acceptable from the first dose of study drug until the end of trial (EoT) visit. Acceptable methods of birth control are:
combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation:
progestogen-only hormonal contraception associated with inhibition of ovulation:
This condition is waived if the participant is proven to have no child-bearing potential (eg, hysterectomy).
Exclusion Criteria:
Is a female who is pregnant, breast-feeding or intends to become pregnant during the planned course of the study. Note: Participants must have a negative serum pregnancy test (β-human chorionic gonadotropin (β-hCG)) performed by the central laboratory prior to enrollment in the study and negative urine pregnancy result at the randomization visit.
Migraine history related
Participant is taking migraine prophylactic medication where the prescribed daily dose has changed during the 3 months prior to screening (Visit 1) or anticipates any change during the study. Any withdrawal of preventive medications for the treatment of migraine should be completed at least 30 days prior to screening.
Medical history related
Participant has a history of gastric or small intestinal surgery (including gastric bypass surgery or banding but not including cholecystectomy or appendectomy) or has a disease that causes malabsorption.
Laboratory, vital sign, and (ECG) related
Has a mean value for triplicate seated systolic blood pressure >160 mmHg and/or diastolic blood pressure (BP) >95 mmHg measured after at least 5 minutes at rest at the Screening Visit.
Note: If a participant's BP is exclusionary on the first triplicate assessment at the Screening Visit, they may have 1 repeat triplicate BP assessment at that visit after another rest of at least 10 minutes.
Medication use and substance abuse related
History of non-narcotic analgesic intake on greater than/equal 15 days per month for greater than/equal 3 months prior to screening.
Other
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a single dose of elismetrep 2 mg
Drug: Elismetrep (K-304) 2 mg
Participants received a single dose of elismetrep 5 mg
Drug: Elismetrep (K-304) 5 mg
Participants received a single dose of elismetrep 10 mg
Drug: Elismetrep (K-304) 10 mg
Participants received a single dose of elismetrep 20 mg
Drug: Elismetrep (K-304) 20 mg
Participants received a single dose of elismetrep-matched placebo
Drug: Placebo
Administered orally
Administered orally
Administered orally
Administered orally
Administered orally
Pain Freedom
Assessed using the number of evaluable participants that reported no pain at 2 hours post-dose. Pain was measured on a 4-point Likert scale (0 = none, 1 = mild, 2 = moderate, 3 = severe)
Time frame: 2 hours post-dose
Freedom From the Most Bothersome Symptom (MBS) (Nausea, Phonophobia or Photophobia)
Assessed using the number of evaluable participants that reported the absence of their MBS
Time frame: 2 hours post-dose
Pain Relief
Assessed using the number of evaluable participants that reported a pain level of moderate or severe (responses of 2 or 3 on the 4-point Likert scale) at baseline and then reported a pain level of none or mild (response of 0 or 1).
Time frame: 2 hours post-dose
Freedom From Photophobia
Assessed by tabulating the number of participants that reported the absence of photophobia at 2 hours post-dose in the subset of participants that reported the presence of photophobia at baseline.
Time frame: 2 hours post-dose
Freedom From Phonophobia
Assessed by tabulating the number of participants that reported the absence of phonophobia at 2 hours post-dose in the subset of participants that reported the presence of phonophobia at baseline.
Time frame: 2 hours post-dose
Freedom From Nausea
Assessed by tabulating the number of participants that reported the absence of nausea at 2 hours post-dose in the subset of participants that reported the presence of nausea at baseline.
Time frame: 2 hours post-dose
The Probability of Requiring Rescue Medication
Assessed using the number of participants that took rescue medication within 24 hours after administration of study therapy
Time frame: 24 hours post-dose
Sustained Pain Freedom
Assessed using the number of participants that did not experience any headache pain through the time period of interest
Time frame: From 2 to 24 hours
Sustained Pain Relief
Assessed using the number of participants that did not experience any moderate or severe headache pain through the time period of interest.
Time frame: From 2 to 24 hours
Sustained Pain Freedom
Assessed using the number of participants that did not experience any headache pain through the time period of interest.
Time frame: From 2 to 48 hours
Sustained Pain Relief
Assessed using the number of participants that did not experience any moderate or severe headache pain through the time period of interest.
Time frame: From 2 to 48 hours
Proportion of Participants Who Experienced 1 or More Treatment-emergent Adverse Events (AEs)
Time frame: up to 7 days after administration of study therapy
Proportion of Participants Who Experienced 1 or More Treatment-emergent Serious Adverse Events (SAEs)
Serious adverse events were assessed in the Safety Analysis Set.
Time frame: Up to 7 days after administration of study therapy
| Milestone | Elismetrep (K-304) 2 mg | Elismetrep (K-304) 5 mg | Elismetrep (K-304) 10 mg | Elismetrep (K-304) 20 mg | Placebo |
|---|---|---|---|---|---|
| Started | 54 | 107 | 108 | 54 | 108 |
| Completed | 54 | 106 | 106 | 54 | 106 |
| Not completed | 0 | 1 | 2 | 0 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 | 2 | 0 | 2 |
Assessed using the number of evaluable participants that reported no pain at 2 hours post-dose. Pain was measured on a 4-point Likert scale (0 = none, 1 = mild, 2 = moderate, 3 = severe)
| Participants | Elismetrep (K-304) 2 mg | Elismetrep (K-304) 5 mg | Elismetrep (K-304) 10 mg | Elismetrep (K-304) 20 mg | Placebo |
|---|---|---|---|---|---|
| Pain Freedom | 4 | 10 | 10 | 9 | 9 |
Assessed using the number of evaluable participants that reported the absence of their MBS
| Participants | Elismetrep (K-304) 2 mg | Elismetrep (K-304) 5 mg | Elismetrep (K-304) 10 mg | Elismetrep (K-304) 20 mg | Placebo |
|---|---|---|---|---|---|
| Freedom From the Most Bothersome Symptom (MBS) (Nausea, Phonophobia or Photophobia) | 12 | 38 | 28 | 18 | 23 |
Assessed using the number of evaluable participants that reported a pain level of moderate or severe (responses of 2 or 3 on the 4-point Likert scale) at baseline and then reported a pain level of none or mild (response of 0 or 1).
| Participants | Elismetrep (K-304) 2 mg | Elismetrep (K-304) 5 mg | Elismetrep (K-304) 10 mg | Elismetrep (K-304) 20 mg | Placebo |
|---|---|---|---|---|---|
| Pain Relief | 29 | 56 | 50 | 30 | 42 |
Assessed by tabulating the number of participants that reported the absence of photophobia at 2 hours post-dose in the subset of participants that reported the presence of photophobia at baseline.
| Participants | Elismetrep (K-304) 2 mg | Elismetrep (K-304) 5 mg | Elismetrep (K-304) 10 mg | Elismetrep (K-304) 20 mg | Placebo |
|---|---|---|---|---|---|
| Freedom From Photophobia | 11 | 23 | 18 | 13 | 26 |
Assessed by tabulating the number of participants that reported the absence of phonophobia at 2 hours post-dose in the subset of participants that reported the presence of phonophobia at baseline.
| Participants | Elismetrep (K-304) 2 mg | Elismetrep (K-304) 5 mg | Elismetrep (K-304) 10 mg | Elismetrep (K-304) 20 mg | Placebo |
|---|---|---|---|---|---|
| Freedom From Phonophobia | 12 | 29 | 23 | 11 | 22 |
Assessed by tabulating the number of participants that reported the absence of nausea at 2 hours post-dose in the subset of participants that reported the presence of nausea at baseline.
| Participants | Elismetrep (K-304) 2 mg | Elismetrep (K-304) 5 mg | Elismetrep (K-304) 10 mg | Elismetrep (K-304) 20 mg | Placebo |
|---|---|---|---|---|---|
| Freedom From Nausea | 12 | 25 | 24 | 13 | 23 |
Assessed using the number of participants that took rescue medication within 24 hours after administration of study therapy
| Participants | Elismetrep (K-304) 2 mg | Elismetrep (K-304) 5 mg | Elismetrep (K-304) 10 mg | Elismetrep (K-304) 20 mg | Placebo |
|---|---|---|---|---|---|
| The Probability of Requiring Rescue Medication | 15 | 24 | 25 | 16 | 27 |
Assessed using the number of participants that did not experience any headache pain through the time period of interest
| Participants | Elismetrep (K-304) 2 mg | Elismetrep (K-304) 5 mg | Elismetrep (K-304) 10 mg | Elismetrep (K-304) 20 mg | Placebo |
|---|---|---|---|---|---|
| Sustained Pain Freedom | 2 | 7 | 10 | 6 | 7 |
Assessed using the number of participants that did not experience any moderate or severe headache pain through the time period of interest.
| Participants | Elismetrep (K-304) 2 mg | Elismetrep (K-304) 5 mg | Elismetrep (K-304) 10 mg | Elismetrep (K-304) 20 mg | Placebo |
|---|---|---|---|---|---|
| Sustained Pain Relief | 19 | 39 | 34 | 15 | 26 |
Assessed using the number of participants that did not experience any headache pain through the time period of interest.
| Participants | Elismetrep (K-304) 2 mg | Elismetrep (K-304) 5 mg | Elismetrep (K-304) 10 mg | Elismetrep (K-304) 20 mg | Placebo |
|---|---|---|---|---|---|
| Sustained Pain Freedom | 2 | 6 | 8 | 6 | 5 |
Assessed using the number of participants that did not experience any moderate or severe headache pain through the time period of interest.
| Participants | Elismetrep (K-304) 2 mg | Elismetrep (K-304) 5 mg | Elismetrep (K-304) 10 mg | Elismetrep (K-304) 20 mg | Placebo |
|---|---|---|---|---|---|
| Sustained Pain Relief | 16 | 35 | 29 | 14 | 21 |
| Participants | Elismetrep (K-304) 2 mg | Elismetrep (K-304) 5 mg | Elismetrep (K-304) 10 mg | Elismetrep (K-304) 20 mg | Placebo |
|---|---|---|---|---|---|
| Proportion of Participants Who Experienced 1 or More Treatment-emergent Adverse Events (AEs) | 3 | 8 | 18 | 21 | 4 |
Serious adverse events were assessed in the Safety Analysis Set.
| Participants | Elismetrep (K-304) 2 mg | Elismetrep (K-304) 5 mg | Elismetrep (K-304) 10 mg | Elismetrep (K-304) 20 mg | Placebo |
|---|---|---|---|---|---|
| Proportion of Participants Who Experienced 1 or More Treatment-emergent Serious Adverse Events (SAEs) | 0 | 0 | 0 | 0 | 0 |
Collected over Up to 7 days after administration of study therapy. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Elismetrep (K-304) 2 mg | 0/51 (0%) | 0/51 (0%) | 2/51 (3.9%) |
| Elismetrep (K-304) 5 mg | 0/101 (0%) | 0/101 (0%) | 1/101 (1%) |
| Elismetrep (K-304) 10 mg | 0/97 (0%) | 0/97 (0%) | 10/97 (10.3%) |
| Elismetrep (K-304) 20 mg | 0/51 (0%) | 0/51 (0%) | 19/51 (37.3%) |
| Placebo | 0/104 (0%) | 0/104 (0%) | 0/104 (0%) |
| Event | Elismetrep (K-304) 2 mg | Elismetrep (K-304) 5 mg | Elismetrep (K-304) 10 mg | Elismetrep (K-304) 20 mg | Placebo |
|---|---|---|---|---|---|
| Feeling hotGeneral disorders | 0/51 | 0/101 | 4/97 | 5/51 | 0/104 |
| Paresthesia oralGastrointestinal disorders | 0/51 | 0/101 | 2/97 | 5/51 | 0/104 |
| Hot flushVascular disorders | 0/51 | 0/101 | 1/97 | 4/51 | 0/104 |
| ParesthesiaNervous system disorders | 0/51 | 0/101 | 5/97 | 4/51 | 0/104 |
| FlushingVascular disorders | 2/51 | 1/101 | 4/97 | 3/51 | 0/104 |
Modified Intent-to-Treat (ITT) Set including randomized participants who took study therapy, had a qualifying migraine of moderate or severe baseline pain intensity (Grade 2 or 3, on a 4-point numeric rating), and provided baseline and at least one post-baseline efficacy data point (i.e. non-missing pain level, phonophobia status, photophobia status, nausea status etc).
| Age, Continuous(years) | Elismetrep (K-304) 2 mg | Elismetrep (K-304) 5 mg | Elismetrep (K-304) 10 mg | Elismetrep (K-304) 20 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 44.5 ± 10.13 | 44.5 ± 13.12 | 46.1 ± 12.68 | 47.4 ± 13.96 | 46.5 ± 11.44 | 45.8 ± 12.36 |
| Sex: Female, Male(Participants) | Elismetrep (K-304) 2 mg | Elismetrep (K-304) 5 mg | Elismetrep (K-304) 10 mg | Elismetrep (K-304) 20 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 43 | 89 | 86 | 44 | 84 | 346 |
| Male | 8 | 12 | 10 | 7 | 15 | 52 |
| Race (NIH/OMB)(Participants) | Elismetrep (K-304) 2 mg | Elismetrep (K-304) 5 mg | Elismetrep (K-304) 10 mg | Elismetrep (K-304) 20 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 0 | 1 | 2 |
| Asian | 2 | 2 | 2 | 1 | 4 | 11 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 9 | 24 | 10 | 7 | 17 | 67 |
| White | 40 | 71 | 81 | 43 | 74 | 309 |
| More than one race | 0 | 2 | 2 | 0 | 1 | 5 |
| Unknown or Not Reported | 0 | 2 | 0 | 0 | 2 | 4 |
| Ethnicity (NIH/OMB)(Participants) | Elismetrep (K-304) 2 mg | Elismetrep (K-304) 5 mg | Elismetrep (K-304) 10 mg | Elismetrep (K-304) 20 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 5 | 11 | 11 | 6 | 12 | 45 |
| Not Hispanic or Latino | 46 | 89 | 84 | 44 | 87 | 350 |
| Unknown or Not Reported | 0 | 1 | 1 | 1 | 0 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2025 to primary completion in Aug 2025, 4 months.
Results were first posted in Aug 2026, 1 year after primary completion.
Of 43 industry-sponsored phase 2 interventional studies under Migraine Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 4 months is below that.
Counting every sponsor, half of 73 studies reached it within 15 months; a quarter within 11 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elismetrep
TriGemX Bio, Inc.